| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | 20.4 | -42.2 |
| EPS (diluted, $ a share) | $0.07 | $-0.16 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: SANA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Sana Biotechnology, Inc.: key numbers
- Share price
- $1.88Close, Nov 16
- Market cap
- $563M
- Shares outstanding
- 299.63MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Sana Biotechnology, Inc.
All →Sana Biotechnology Financial Results
Sana Biotechnology reported third quarter 2026 financial results, highlighting a cash position of $121.7 million and a cash runway expected to last into mid-2027. The company is progressing toward initiating clinical trials for its type 1 diabetes candidate SC451 and its non-Hodgkin lymphoma candidate SG293, with data readouts anticipated in 2027.
“We continue to make meaningful progress toward initiating clinical studies of SC451 later this year and SG293 in 1Q 2027. We aim to share data from both of these programs in 2027 and anticipate both have the potential for relatively rapid proof of concept. In particular, SC451 in type 1 diabetes may provide a rapid signal, similar to what was seen with UP421, on whether the therapy can evade immune detection and function in patients.”
Steve Harr, Sana’s President and Chief Executive Officer